Varenicline Tartrate

Nicotine e-cigarettes may be one of the most effective tools yet for quitting smoking, according to a sweeping review of global research. By analyzing findings from 14 major reviews spanning nearly a decade, researchers found consistent, high-quality evidence showing that nicotine vapes outperform traditional methods like patches, gum, and even behavioral support. While some lower-quality studies produced mixed results, the strongest data clearly favored nicotine e-cigarettes.A comprehensive review of global research on smoking cessation suggests that e-cigarettes containing nicotine may help more people quit smoking than other commonly used methods. These include nicotine replacement therapy (nicotine patches, gum, lozenges, etc.) as well as non-nicotine e-cigarettes and behavioral support programs. The analysis brings together findings from multiple systematic reviews to provide a clearer picture of what works best for quitting smoking. In total, researchers combined results from fourteen systematic reviews conducted between 2014 and 2023, making the evidence easier to interpret and compare. Strongest Evidence Favors Nicotine E-Cigarettes When focusing on the highest-quality studies, the results consistently show that nicotine e-cigarettes lead to higher quit rates than other approaches. In contrast, lower-quality studies produced less consistent and more uncertain findings. Overall, the most reliable evidence points to nicotine e-cigarettes outperforming nicotine replacement therapy, non-nicotine e-cigarettes, and other alternatives. As part of the project, researchers developed an 'Evidence and Gap Map' (EGM) to highlight areas where more research is needed. Currently, there are no high-quality systematic reviews directly comparing nicotine e-cigarettes with treatments such as cytisine, bupropion, or nicotine pouches. Evidence comparing e-cigarettes with varenicline is also very limited, based on just one small study with a high risk of bias. The EGM also indicates that evidence on serious adverse events linked to e-cigarettes remains uncertain. In addition, most of the available data comes from high-income countries. Researchers emphasize the need for future studies to better track potential risks and to include populations from low-and middle-income countries. Researchers Say Evidence Is Clear Lead author Dr. Angela Difeng Wu, Senior Researcher and Lecturer at the Nuffield Department of Primary Care Health Sciences, University of Oxford, says "We hope this overview and Evidence and Gap Map can lay to rest some claims that evidence is 'mixed' regarding the impacts of nicotine e-cigarettes on smoking abstinence. In fact, the evidence is clear and consistent across all of the meta-analyses we consulted: e-cigarettes are effective at helping people stop smoking." This research work was funded by Cancer Research UK, Grant Number PRCPJT‐Nov22/100012.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) disclosed that the US FDA issued a Complete Response Letter for the New Drug Application for reproxalap, an investigational reactive aldehyde species trap, for the treatment of signs and symptoms of dry eye disease. The CRL indicates the FDA determined the application does not currently meet the requirements for approval, citing a lack of substantial evidence of efficacy from the submitted clinical program. The FDA stated that the application “failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The agency noted that inconsistency across study results “raises serious concerns about the reliability and meaningfulness of the positive findings” and that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.” No safety or manufacturing deficiencies were identified. The FDA recommended that Aldeyra explore reasons for trial failures and identify populations or conditions in which reproxalap may demonstrate efficacy. The agency did not recommend conducting additional clinical trials or request submission of additional confirmatory evidence. Reproxalap is a small molecule that functions by covalently binding and sequestering toxic reactive aldehyde species, such as malondialdehyde and 4-hydroxynonenal, which are elevated in inflammatory conditions. This mechanism differs from existing dry eye treatments, which include calcineurin inhibitors such as cyclosporine, corticosteroids such as loteprednol etabonate, and nicotinic acetylcholine receptor agonists such as varenicline nasal spray. The dry eye disease treatment landscape includes several approved therapies — Miebo (perfluorohexyloctane), Tyrvaya (varenicline), Eysuvis (loteprednol etabonate), and Cequa (cyclosporine) — though the company has described reproxalap as, to its knowledge, the only drug with clinical activity within minutes of administration in this patient population. Reproxalap originated from academic research into aldehyde-mediated inflammation and oxidative stress. Aldeyra Therapeutics was founded to translate this science into therapeutic applications and has retained full ownership and development rights throughout the program’s history. No licensing, partnership, or asset transfer arrangements have been publicly disclosed for reproxalap. The company has funded development through public equity offerings and internal resources. During the NDA review period, the FDA provided label drafts in December 2025 and again in March 2026. Aldeyra stated it does not believe label negotiations were completed prior to issuance of the CRL. The provided source material does not reference prior CRLs for reproxalap, prior advisory committee meetings, or approvals in other regulatory jurisdictions. This appears to be the first CRL issued for this NDA. Aldeyra stated it intends to request a Type A meeting with the FDA to understand the actions needed for NDA approval. Per Prescription Drug User Fee Act goals, the target date for a Type A meeting is within 30 days of receipt of the meeting request. The company stated it does not currently expect to pursue additional clinical trials. Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, said the company would “work with urgency to support the FDA in enabling market access.” As of December 31, 2025, Aldeyra reported cash, cash equivalents, and marketable securities of $70 million, which the company expects to support operations into 2028. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website